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Abstract
Context: TAC3/TACR3 mutations have been reported in normosmic congenital hypogonadotropic hypogonadism (nCHH)
(OMIM #146110). In the absence of animal models, studies of human neuroendocrine phenotypes associated with
neurokinin B and NK3R receptor dysfunction can help to decipher the pathophysiology of this signaling pathway.
Objective: To evaluate the prevalence of TAC3/TACR3 mutations, characterize novel TACR3 mutations and to analyze
neuroendocrine profiles in nCHH caused by deleterious TAC3/TACR3 biallelic mutations.
Results: From a cohort of 352 CHH, we selected 173 nCHH patients and identified nine patients carrying TAC3 or TACR3
variants (5.2%). We describe here 7 of these TACR3 variants (1 frameshift and 2 nonsense deleterious mutations and 4
missense variants) found in 5 subjects. Modeling and functional studies of the latter demonstrated the deleterious
consequence of one missense mutation (Tyr267Asn) probably caused by the misfolding of the mutated NK3R protein. We
found a statistically significant (p,0.0001) higher mean FSH/LH ratio in 11 nCHH patients with TAC3/TACR3 biallelic
mutations than in 47 nCHH patients with either biallelic mutations in KISS1R, GNRHR, or with no identified mutations and
than in 50 Kallmann patients with mutations in KAL1, FGFR1 or PROK2/PROKR2. Three patients with TAC3/TACR3 biallelic
mutations had an apulsatile LH profile but low-frequency alpha-subunit pulses. Pulsatile GnRH administration increased
alpha-subunit pulsatile frequency and reduced the FSH/LH ratio.
Conclusion: The gonadotropin axis dysfunction associated with nCHH due to TAC3/TACR3 mutations is related to a low
GnRH pulsatile frequency leading to a low frequency of alpha-subunit pulses and to an elevated FSH/LH ratio. This ratio
might be useful for pre-screening nCHH patients for TAC3/TACR3 mutations.
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Introduction
In the last two years, loss-of-function mutations in TAC3 (MIM
162330) and TACR3 (MIM 162332), the genes encoding
neurokinin B (NKB) and its receptor NK3R, respectively, have
been described in patients with non syndromic normosmic
congenital hypogonadotropic hypogonadism (nCHH) (OMIM
#146110), pointing to a fundamental role of this pathway in the
physiology of the human gonadotrope axis [1–5]. The precise
mechanisms by which these mutations cause gonadotropin
deficiency and CHH are not yet clear [6], although we recently
noted GnRH deficiency in such nCHH patients [3]. In rodents
[7], sheep [8,9], goat [10] and non human primates [11], NKB is
expressed throughout the brain [12] and particularly by the same
neurons that express kisspeptin and dynorphin. In rats, these
neurons form a bilateral, interconnected network that projects to
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Kisspeptins have a recognized effect on GnRH secretion [14]. In
contrast, the neuroendocrine role of NKB is controversial, as
agonists may have either inhibitory or excitatory effects,
depending on the animal model and gender [11,15–18]. In
addition, Tacr3 knock-out mice seem to be fertile [19] and the
phenotype of the murine Tac2 knock-out (ortholog of human
TAC3) has not been yet reported. Detailed neuroendocrine studies
of adult nCHH patients with TAC3/TACR3 mutations may help
to decipher the role of this signaling pathway in the pathophys-
iology of the gonadotrope axis.
The aims of the present work were 1) to evaluate the prevalence
of variants in the TAC3 and TACR3 genes in our cohort of nCHH
patients; 2) to characterize newly identified mutants responsible for
nCHH, at the molecular and functional levels and 3) to examine
the neuroendocrine profile of patients with biallelic TAC3/TACR3
mutations to evaluate the hypothesis that NKB and its receptor
participate in controlling the frequency of GnRH secretory pulses.
Patients
From a cohortof352patients with CHHwe selected 173 patients
with normosmic nCHH and screened for TAC3 and TACR3
mutations. Gonadotropin deficiency in this setting is characterized
by: 1) absent or incomplete puberty at age 18 years; 2) low plasma
testosterone levels in men and low to low-normal estradiol levels in
women plus low or normal serum gonadotropin levels; 3) otherwise
normal pituitary function; 4) normal serum ferritin concentrations;
5) normal magnetic resonance imaging (MRI) of the hypothalamic-
pituitaryregion; and 6) a normal sense of smell on olfactometry, and
no anosmia/hyposmia in relatives [20].
Neuroendocrine profiling of TAC3/TACR3-mutated nCHH
patients
Since Topaloglu et al. first reported that TAC3/TACR3
mutations can cause nCHH, studies of published pedigrees have
shown that the transmission of this genetic form is autosomal
recessive [1–4]. Thus, to study the pulsatility of gonadotropin and
free alpha subunit secretion in nCHH patients harboring TAC3/
TACR3 mutations, we enrolled only patients with biallelic
mutations, comprising 2 men partially described elsewhere [3]
and a new female patient (see Case Reports). Free alpha subunit
secretion was evaluated because it has been proposed as the best
surrogate for GnRH secretion in nCHH patients with an
apulsatile LH profile [21–23].
On the same way, for FSH/LH ratio studies, we included 11
patients with biallelic TAC3/TACR3 mutations, of whom 6 are
partially described elsewhere [3] and 5 are novel (see Case
Reports). The FSH/LH ratios in these 11 patients were compared,
using the same assays (see below), with those in patients with CHH
of different genetic origins, namely 4 patients with biallelic
mutations in KISS1R, 11 with biallelic mutations in GNRHR,
32 nCHH patients with no identified mutations in genes known to
cause nCHH and also with those of 50 patients with Kallmann
syndrome and mutations in KAL1 (n=19) or FGFR1 (n=17), or
PROK2/PROKR2 (n=14) (Information S1).
Results
Case reports
In family 1, three sisters were affected. The proband (subject
II-6, Fig. 1A) was a young woman from a consanguineous family
originating from Reunion Island. She was referred at age 24 years
because pubertal development and menses had not occurred. She
had typical signs of complete hypogonadism, with no breast
development but the presence of pubic hair (P4). Her height was
164 cm, her weight 58 kg, and her bone age 14 years. Pelvic
sonography showed a small uterus (34 mm high, 28 mm wide,
22 mm thick) and two small ovaries (right, 0.84 mL; left,
1.48 mL), with a few follicles less than 4 mm in diameter. Her
karyotype was normal (46, XX). Combined estrogen-progestin
replacement therapy induced breast development, an increase in
uterus length, and regular menses. Hormonal evaluation after the
end of this therapy showed that she still had very low estradiol and
LH levels, an undetectable serum inhibin B level, but normal FSH
levels as well as a nonpulsatile LH secretion, and an unchanged
ovarian aspect on sonography. Pulsatile GnRH administration
(90 ng/kg/pulse, every 90 minutes, subcutaneously) was started
because she wished to conceive, resulting in increased circulating
levels of LH, estradiol and inhibin B, appropriate endometrial
thickening, and recruitment of a single dominant follicle of
20 mm. Eleven days later, while still receiving pulsatile GnRH
therapy, her progesterone concentration rose to a luteal-phase
level (19 ng/mL) and ultrasonography showed the typical aspect of
a corpus luteum. This patient’s older affected sister (subject II-5,
Fig. 1A), who was evaluated at age 21 years, also had complete
hypogonadism and a normal sense of smell. At diagnosis, she had
no breast development and sparse pubic hair. Menarche had not
occurred. The proband’s younger affected sister (subject II-8,
Fig. 1A) was 19 years old when first seen for primary amenorrhea
and absent breast development. She was born at term with a
normal birth weight after an uncomplicated pregnancy, and grew
and developed normally until her early to mid-teen years. On
examination, her height was 168 cm and her BMI 23 kg/m
2. She
was at Tanner breast stage 1, pubic hair stage 3, and axillary hair
stage 2. Her bone age was 13.5 years at diagnosis.
At diagnosis, the 3 sisters had very low plasma estradiol levels
(7.0, 10.7 and 8.6 pg/mL respectively; normal range in the early
follicular phase: 22–90 pg/mL) and very low serum LH levels
(0.05, 0.1, and 0.16 IU respectively; normal range 2.8–7.1 IU/L),
while their FSH levels were normal for the early follicular phase
(3.7, 4.3, and 4.6 IU/L respectively; normal range: 2.4–7.0 IU/L).
Serum inhibin B levels were undetectable (,10 pg/mL) in the
propositus and her older affected sister at diagnosis.
The family 2 proband (subject II–1, Fig. 1B) was a Caucasian
French man born to non consanguineous eugonadal French
parents. He was referred at age 19 years-old for absent pubertal
development. Physical examination showed typical signs of
hypogonadism, with small testes (mean volume: 0.8 mL, normal
range in men: 15–30 mL). His height was 180 cm and his weight
68 kg. His karyotype was normal (46, XY). His medical history
indicated that he was first referred to a pediatric endocrinologist at
age 8 years for micropenis (2.5 cm) and bilateral cryptorchidism,
for which he was operated on at age 19 years. At diagnosis he had
very low levels of plasma testosterone (0.2 ng/mL; normal range:
2.8–9.0 ng/mL) and serum LH (0.2 IU/L), but his serum FSH
(5.4 IU/L) was normal for age and responded (peak: 8.0 IU/L) to
GnRH challenge (100 mg intravenously). He was recently
reevaluated in September 2010 at 46 years old after a four
months interruption of androgen therapy: mean testicular volume
was at 1 mL, serum testosterone (0.3 ng/mL) and serum inhibin B
(12 pg/mL) were very low; serum LH was low (0.3 IU/L) and
FSH was in the normal range (4.4 IU/L).
The family 3 proband (subject II-1, Fig. 1C) was a Caucasian
French man born to non consanguineous eugonadal French
parents. He was referred at age 18 years for absent pubertal
development. Physical examination showed typical signs of
hypogonadism, with small intrascrotal testes (2 mL). His height
was 183 cm and his weight 65 kg. His karyotype was normal (46,
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25614Figure 1. Family pedigrees and consequences of TACR3 mutations on NK3R structure. Panel A. Pedigree of the family with homozygous
TACR3 c.483_499 deletion. The proband, subject II-6 (arrow), and her two affected sisters (subjects II-5 and II-8), were homozygous for the c.483_499
deletion. The unaffected father (I-1) was heterozygous for the mutation. The unaffected sister (II-1) carried homozygous wild-type alleles. This
deletion results in the emergence of a premature stop codon (Q161HfsX23), truncating NK3R after the third transmembrane segment. Panel B.
Pedigree of the family with compound heterozygous TACR3 mutations c.824G.A and c.1003C.T. The proband, subject II-1 (arrow), was compound
heterozygous for TACR3 mutations c.824G.A and c.1003C.T. The unaffected father (I-1) was heterozygous for the c.824G.A mutation and the
unaffected mother was heterozygous for the c.1003C.T mutation. The c.824G.A substitution produces a stop codon in the 5
th transmembrane
segment (p.W275X) of NK3R. The c.1003C.T substitution produces a stop codon in the junction between the third extracellular loop and the seventh
transmembrane domain (p.Q335X) of NK3R. Panel C. Pedigree of the family with compound heterozygous TACR3 mutations c.799T.A and c.824G.A.
The proband, subject II-1 (arrow), was compound heterozygous for TACR3 mutations c.799T.A and c.824G.A. The unaffected father (I-1) was
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and serum LH (0.65 IU/L), but his serum FSH (5.6 IU/L) was
normal for age and responded excessively (peak: 11.5 IU/L) to
GnRH challenge. Interestingly, his medical history indicated that
he was first referred to a pediatric endocrinologist at age
20 months for micropenis (2.3 cm) and right cryptorchidism, for
which he was operated on at age 9 years. At age 20 months his
levels of testosterone (0.1 ng/mL; normal range: 0.05–0.45) and
LH (0.6 IU/L; normal range: 0.1–1.1 IU/L) were in the normal
range for chronological age but the FSH was slightly elevated and
responded excessively to GnRH challenge (from 2.2 (basal) to
11.2 IU/L (peak); normal range at 20 months: basal, 0.2–1.6 IU/
L; peak, 2.3–5.9 IU/L) [24].
All the patients studied here had normal MRI of pituitary gland
and olfactory bulbs, normal sense of smell on olfactometry and
had no renal or craniofacial abnormalities, normal circulating
iron, ferritin, and prolactin levels, and normal pituitary, adrenal
and thyroid function. None had any other clear neurobehavioral
or other phenotypic abnormalities (bimanual synkinesia, dysmor-
phic facial features, midline anomalies, hearing loss, hypotonia,
ataxia, dementia, or polyneuropathy). In particular, all had normal
learning ability.
Molecular analysis
The GNRH1, GNRHR, KISS1, KISS1R and FGFR1 exons and
intron–exon boundaries were identical to the reference sequences in
all the 173 patients studied. Of these 173 patients, 9 propositi (5.2%)
carriedTAC3/TACR3variants(1inTAC3and8inTACR3)(Table1
and Fig. S1). Two of these mutations, 1 in TAC3 and 1 in TACR3,
found in 4 propositi, were previously reported [3]. Here we describe
7 additional different TACR3 variants (5 original and 2 recurrent) in
5 unrelated nCHH propositi (Table 1). Among them, 3 propositi
carried biallelic TACR3 mutations (see case reports), one propositus
being homozygous (Fig. 1A), and two compound heterozygotes
(Fig. 1B and 1C). In addition, we found 3 monoallelic TACR3
variants in two nCHH propositi (Figs. S3 and S4).
In family 1 propositus, as well as in her affected sisters, we found
a homozygous TACR3 deletion (c.483_499del) (subjects II-
6, II-5 and II-8, Fig. 1A and Fig. S2 panel A). The mutation was
found in the heterozygous state in the patient’s unaffected father
(subject I-1, Fig. 1A and Fig. S2). The unaffected sister (subject II-
1, Fig. 1A) was a wild-type homozygote (Fig. S2). This deletion
results in a frameshift from codon 161 and the emergence of a
premature stop codon at position 183 (Gln161HisfsX23), truncat-
ing NK3R after the third transmembrane segment (Fig. 1A and
Fig. S1). This deletion was not found by genomic sequencing in
200 chromosomes from eugonadal ethnically matched subjects.
In propositus II.1 from family 2 (Fig. 1B) we found a
compound heterozygous TACR3 mutation (c.824G.A
and c.1003C.T). The c.824G.A substitution produces a stop
codon in the 5
th transmembrane segment (p.Trp275Stop) of
NK3R (Fig. 1B, Fig. S1 and Fig. S2, panel B). This recurrent
mutation has previously been reported in the homozygous and
monoallelic states by Gianetti et al. [4]. It was found in the
heterozygous state in the unaffected father. The c.1003C.T
substitution which produces a stop codon in the junction between
the third extracellular loop and the seventh transmembrane
domain (p.Gln335Stop) of NK3R (Fig. 1B, Fig. S1) was found in
the heterozygous state in the unaffected mother. These 2
mutations were not found by genomic sequencing in 200
chromosomes from ethnically matched eugonadal control subjects.
In propositus II.1 from family 3 (Fig. 1C) we found a
compound heterozygous TACR3 mutation (c.799T.A
and c.824G.A). The p.Trp275stop recurrent mutation was
found in the heterozygous state in the unaffected father (Fig. S2,
panel C). The c.799T.A substitution, which produces a missense
mutation (p.Tyr267Asn) located in the fifth transmembrane
segment of NK3R (Fig. 1C), was found in the heterozygous state
in the unaffected mother (Fig. S2, panel C). These 2 mutations
were not found by genomic sequencing in 200 chromosomes from
ethnically matched eugonadal control.
Modeling and functional studies of the missense
mutations
The Tyr267 residue is highly conserved among the three human
tachykinin receptors and in all NK3R orthologs (Fig. 2A). Modeling
was used to predict the potential impact of this point mutation on
the three-dimensional organization of NK3R. We found that the
Table 1. One TAC3 and 8 TACR3* variants found in 9 propositi from a cohort of 173 normosmic CHH evaluated at Bice ˆtre Hospital.
Gene Nucleotides change Protein change Fonctional consequences Comment
TACR3 c.483_499del Q161H fsX23 PTC/TP novel
TACR3 c.689 G.A R230H no novel
TACR3 c.738-1 G.A Y247L fsX4 PTC/TP reported in ref. 3
TACR3 c.799 T.A Y267N decrease MAPK activity novel
TACR3 c.824 G.A W275X PTC/TP recurrent in ref. 4
TACR3 c.857 A.G K286R no recurrent (rs2276973)
TACR3 c.918 G.A M306I no novel
TACR3 c.1003 C.T Q335X PTC/TP novel
TAC3 c.209-1 G.C P73I fsX9 PTC/TP reported in ref. 3
PTC/TP: premature termination codon/truncated protein.
*see Fig. S1 in the supporting information.
doi:10.1371/journal.pone.0025614.t001
heterozygous for the recurent c.824G.A mutation and the unaffected mother was heterozygous for the c.799T.A mutation. This latter mutation
affects a conserved amino acid in the fifth transmembrane domain (p.Y267N). Solid symbols indicate affected subjects and half-shaded symbols
indicate unaffected heterozygotes. Circles represent female family members and squares male family members.
doi:10.1371/journal.pone.0025614.g001
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Evolutionary conservation of Tyr267. Tyr267 is perfectly conserved among NK3R orthologs and paralogs. The substitution is indicated below. Panel B.
Modeling of the transmembrane region of NK3R. The tyrosine 267 and its substitution by an asparagine are pointed at the lipid bilayer. This position
is extremely unfavorable for a polar residue such as asparagine. Panel C. Subcellular localization of ectopically expressed NK3R and Y267N mutant in
non-permeabilized and permeabilized cells. Cells were transfected with the indicated expression vector and then treated for indirect
immunofluorescence as described in the Methods section. The nuclei are counterstained by DAPI (blue). Upper panel: Z-stack projection of NK3R
distribution in non-permeabilized cells obtained by confocal microscopy. Lower panel: fluorescence micrographs of fixed and permeabilized cells.
Note the absence of Y267N NK3R mutant at the membrane (upper) despite its efficient expression in the cell (lower) whereas wild-type NK3R is
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transmembrane segment and points towards the lipid bilayer
(Fig. 2B). Introduction of an asparagine residue at position 267
(Y267N mutation) places a polar residue in a highly hydrophobic
environment. Thus, it is likely that the asparagine side chain, in
order to adopt a buried position, will induce transmembrane
reorganization (twist or rotation). Therefore, the Tyr267Asn
mutation leads probably to NK3R misfolding and dysfunction.
To test this misfolding hypothesis, we performed immunocyto-
chemical studies in both permeabilized and non permeabilized
cells in order to evaluate the subcellular localization of the
Tyr267Asn mutant. In non permeabilized cells the wild-type
NK3R molecule was located at the membrane (Fig. 2C, upper
panel). In contrast, the Tyr267Asn mutant was not detected at the
membrane, suggesting defective trafficking [25]. To ascertain that
the mutant was efficiently expressed, we performed immunocyto-
chemical experiments in permeabilized cells. In this condition,
both wild-type and mutant proteins were detected. Compared to
wild-type, the NK3R mutant was localized in the perinuclear
region suggesting a misfolding (Fig. 2C, lower panel). Thus, the
substitution of Tyr267 by asparagine impaired the proper
targeting of the receptor to the cell surface.
To quantify and compare the stimulation effect of neurokinin B
on wild-type and mutant NK3R, we performed dose-response
curves for SRE luciferase assay in HEK 293T cells. Consistent
with immunocytochemical and modeling studies, functional
analyses clearly showed that mutated NK3R failed to stimulate a
p44/42 MAP-sensitive SRE reporter gene contrary to the wild-
type receptor which showed a clear dose-response stimulation in
the presence of neurokinin B (Fig. 2D).
Similar modeling and functional studies were performed to
characterize separately the 3 other variants (Lys286Arg, Me-
t306Ile and Arg230His). In addition, the two Lys286Arg and
Met306Ile mutations located on the same chromosome were
assessed as double mutant. These analyses, detailed in supporting
information (Fig. S3 and Fig. S4), suggest that in fact these variants
did not affect the structure and the function of NK3R. Therefore
they can not be considered as causative of the disease. For that
reason, clinical features of these propositi were not detailed here.
Analysis of free alpha subunit (FAS) and gonadotropin
pulsatility in nCHH patients with biallelic TAC3 or TACR3
mutations
Serum FAS pulsatility was analyzed in subject II.6 from family 1
(Fig. 1A and Table 2), who harbored a homozygous mutation in
TACR3, and in two subjects partially described elsewhere [3] with
either a homozygous TAC3 or a homozygous TACR3 mutation.
Endogenous serum FAS levels are shown for two of these subjects
in Fig. 3A and 3B.
Mean (6SD) basal FAS concentrations in these 3 patients were
low (0.1960.05 IU/L), with a low mean pulse frequency (1.261.3
pulses every four hours (mean6SD); normal range: 2.3–3.0) and a
low amplitude of detected pulses (0.260.1 IU/L). As expected,
pulsatile GnRH administration to these 3 nCHH patients
significantly (p,0.01) increased mean FAS levels (1.160.19 IU/
L) and the FAS pulse frequency (3.360.6 pulses every four hours)
and amplitude (0.4160.11 IU/L, P,0.05), in line with GnRH
dependency of pituitary FAS secretion [23].
Analysis of basal LH and FSH secretion overnight at 10-min
intervals for 4 h in subject II.6 from family 1 (Fig. 1A and Table 2)
showed very low levels and a nonpulsatile pattern of LH secretion,
whereas mean baseline FSH levels were significantly higher
(Fig. 3C). On day 13 of pulsatile GnRH administration (90 ng/
kg/pulse, every 90 min, sc), pulses of LH were detected,
synchronously with the GnRH boluses (Fig. 3D) and concomi-
tantly with an increase in serum estradiol and inhibin B levels and
a slight serum FSH decrease.
localized at the plasma membrane. Panel D. NKB dose response of the reporter luc2P/SRE. Increasing concentrations of NKB led to an increase in the
luciferase activity of wild-type NK3R (black circles). The mutant NK3R (red triangles) did not significantly enhance luciferase activity.
doi:10.1371/journal.pone.0025614.g002
Table 2. Characteristics of nCHH patients with biallelic TACR3 or TAC3 deleterious mutations selected for FSH/LH ratio calculation.
Cases Age FSH/LH Ratio Sex Gene Nucleotides change References
1* 24 74.0 Female TACR3 c.[483_499del]+[483_499del] Subject II-5 Family 1 present
study
2* 21 43.0 Female TACR3 c.[483_499del]+[483_499del] Subject II-6 Family 1 present
study
3* 19 28.7 Female TACR3 c.[483_499del]+[483_499del] Subject II-8 Family 1 present
study
4 19 27.5 Male TACR3 c.[824 G.A]+[1003 C.T] Subject II-1 Family 2 present
study
5 18 8.6 Male TACR3 c.[799 T.A]+[824 G.A] Subject II-1 Family 3 present
study
6** 28 8.0 Male TACR3 c.[738-1 G.A]+[738-1 G.A] Subject II-1 Family 4 in ref. 3
7** 26 10.5 Female TACR3 c.[738-1 G.A]+[738-1 G.A] Subject II-5 Family 4 in ref. 3
8** 23 13.0 Female TACR3 c.[738-1 G.A]+[738-1 G.A] Subject II-7 Family 4 in ref. 3
9 31 32.0 Male TAC3 c.[209-1 G.C]+[209-1 G.C] Subject II-1 Family 1 in ref. 3
10 21 39.0 Male TAC3 c.[209-1 G.C]+[209-1 G.C] Subject II-1 Family 2 in ref. 3
11 26 6,6 Female TAC3 c.[209-1 G.C]+[209-1 G.C] Subject II-1 Family 3 in ref. 3
*members of the same kindred.
**members of the same kindred.
doi:10.1371/journal.pone.0025614.t002
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The FSH/LH ratios in 11 subjects with biallelic TAC3/TACR3
mutations (Table 2) are shown in Fig. 4A. Compared to subjects with
other known genetic causes of nCHH KISS1R (mean (6SD) FSH/
LH=3.262.4), GNRHR (mean FSH/LH=1.360.5) mutations or
Kallmann syndrome (KAL1:mean FSH/LH=1.260.6), FGFR1
(mean FSH/LH=1.560.5) and PROK2 or PROKR2 mutations
(mean FSH/LH=1.761.4)(Information S1) and to 32 patients with
nCHH (mean FSH/LH=1.260.8) and no identified genetic
anomalies, patients with TAC3/TACR3 mutations had very signifi-
cantly (p,0.001 for each comparison, see Fig. 4A) higher FSH/LH
ratios (mean FSH/LH= 23.6622.4). Finally, we observed a decline
in the FSH/LH ratio in the three subjects (patient II-6 family 1 and in
the two nCHH subjects with respectively TAC3 and TACR3
mutations in part reported in ref 3) who received pulsatile GnRH
administration (from 18.4617.9 to 0.860.2)(Fig. 4B).
Discussion
We found here TAC3/TACR3 mutations in 5.2% of our nCHH
population, a prevalence similar to that described by Gianetti et al
[4] in a population of Caucasians, Asians and African-Americans.
In this series, all the subjects with nCHH and biallelic TAC3/
TACR3 mutations were born to healthy heterozygous parents. This
reinforces the autosomal recessive transmission of these two genetic
forms of nCHH, as reported by Topaloglu et al. and us [1–3].
In the first family, we identified a new homozygous mutation in
TACR3 that leads to a frameshift and truncation of the receptor
after the third transmembrane domain and therefore almost
certainly has a deleterious effect. In two french families of
Caucasian origin we found three TACR3 mutations with
compound heterozygous status. They share the same mutation,
which generates a stop codon (Trp275stop) and leads to truncation
of the protein after the fifth transmembrane domain, indicating
that it is also certainly deleterious. This recurrent mutation has
been found in the homozygous state in Caucasian American
patients with nCHH [4], suggesting either a founder effect in this
population or a mutation hotspot in this genomic region. The
propositus of the second family also carried on the other allele a
novel non sens mutation (Gln335stop) which leads to truncation of
the protein after the third extra cellular loop also indicating that it
is certainly deleterious. The propositus of the third family also
carried a new missense mutation, Tyr267Asn, on the other allele,
as revealed by studies of the parents. This mutation, affecting a
conserved amino acid in the fifth transmembrane domain, affects
the conformation of this domain, as shown by molecular modeling.
The deleterious nature of this variant was confirmed by functional
analyses showing altered MAP kinase-mediated NK3R signaling.
This dysfunction is likely due to receptor misfolding and to
defective plasma membrane targeting, as shown by immunocyto-
chemical studies. Such a mechanism has already been reported for
mutations affecting another 7-transmembrane-domain receptor
(GnRHR) and leading to nCHH [25].
Analysis of gonadotropin concentrations in patients with
biallelic TAC3/TACR3 mutations showed very weak and apulsatile
LH secretion, contrasting with preserved FSH concentrations.
This profile, already found in other nCHH patients with biallelic
TAC3/TACR3 mutations [1,3], points to the existence of low-
frequency (and probably low amplitude) endogenous GnRH
Figure 3. Secretory free alpha-subunit (FAS) and gonadotropin responses to pulsatile GnRH administration. Panel A. FAS
concentrations in a man with nCHH caused by a homozygous TAC3 c.209-1G.C mutation, before and on day 19 of pulsatile GnRH administration
(patient reported in part in [3]). Arrows indicate exogenous GnRH boluses (7 mg). Panel B. FAS concentration in a woman with nCHH caused by a
mutation in TACR3 (subject II-6 in family I, Fig. 1A), before and on day 13 of pulsatile GnRH administration. Arrows indicate exogenous GnRH boluses
(5 mg). Asterixes denote detectable FAS pulses, using Thomas’ algorithm [24]. See Patients and Methods for details. Panel C. Pattern of gonadotropin
secretion in a woman with complete nCHH and TACR3 mutation (subject II-6 in family I, Fig. 1A). Basal LH concentration was very low and FSH
concentration was in the normal range. Panel D. LH pulsatility in this woman was restored by pulsatile GnRH administration, and the serum FSH level
fell slightly during pulsatile GnRH administration. Serum estradiol (E2) and inhibin B (IB) levels before and after GnRH administration are indicated
respectively at the top of panel C and D.
doi:10.1371/journal.pone.0025614.g003
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patients studied, strongly supporting this hypothesis. Moreover,
pulsatile GnRH administration at a physiological frequency re-
established pulsatile LH and FAS secretion, and decreased the
FSH/LH ratio. These pattern of response to pulsatile GnRH
treatment are different from those reported in hypothalamic CHH
patients, where GnRH leads to a rise in FSH, sometimes to
supraphysiologic levels [26], further underlining the originality of
the TAC3/TACR3 mutated nCHH patients’ neuroendocrine
phenotype. All these data strongly suggest that the gonadotrope
deficiency in subjects with TAC3/TACR3 mutations is linked to a
slowing of the frequency of endogenous GnRH secretion. It is
therefore likely that neurokinin B, via its receptor NK3R, acts on
the hypothalamus to regulate, either directly or indirectly (via
kisspeptin/dynorphin/NKB neurons)[10,13], the frequency of
GnRH release into the hypothalamo-pituitary portal system.
Our hypothesis is in line with a model recently proposed [10,16]
whereby kisspeptin, Dyn, and NKB act autosynaptically on
kisspeptin neurons in the Arc to shape the pulsatile secretion of
kisspeptin and hence GnRH release.
The molecular mechanisms by which low pattern of pulsatile
GnRH secretion into portal blood favors FSH secretion by
gonadotrope cells remain to be established. In contrast to the LHb
subunit gene, it has been shown in vitro that FSHb subunit
transcription is preferentially stimulated at low rather than high
frequencies of pulsatile GnRH [27]. Because the synthesis of
FSHb is the rate-limiting step in FSH production, how FSHb
transcription is regulated is key to understanding the control of
FSH release. In the context of the rFSHb promoter, Ciconne et al.
had recently established that GnRH stimulates transcription by
increasing bound histone modifying enzyme CBP [28]. This
increase in CBP is mediated in turn through the transcription
factor CREB, bound to the FSH b CRE site. These authors also
showed that mutation of this CRE site abolishes preferential FSH
b transcription at low GnRH pulse frequency, implicating this site
as an important mediator of GnRH pulse frequency-dependent
FSH b gene expression [28].
The existence of a high FSH/LH ratio prior to any treatment in
a significant number of patients with biallelic TAC3/TACR3
mutations, contrary to patients with other genetic causes of CHH,
suggests that this ratio could serve as a diagnostic marker to
prescreen for TAC3/TACR3 mutations in untreated patients with
nCHH. This would narrow down the number of subjects in whom
sequencing is necessary and would thus reduce the cost of genetic
studies in this setting, although larger studies will be necessary
before recommending this diagnostic approach.
All 11 patients with biallelic TAC3/TACR3 mutations that we
have analyzed to date had nCHH persisting into adulthood (from
18 yrs-old to 46 yrs-old). These results, in keeping with data
reported by Topaloglu et al. [1], Guran et al. [2] and Fukami et al.
[5], indicate that NKB and its receptor NK3R are crucial for
physiological GnRH secretion after puberty, and not only during
fetal life as suggested by Gianetti et al. [4]. Furthermore only one
documented case of reversible nCHH in patients with TAC3
biallelic mutations have been reported to date [4], indicating that
this phenomenon does not predominate in this genetic form of
CHH.
In conclusion, TAC3/TACR3 mutations are an important
genetic cause of nCHH that should be particularly searched in
patients with a high serum FSH/LH ratio. Patients with nCHH
and biallelic TAC3/TACR3 mutations represent a useful model for
deciphering the physiological role of NKB and its receptor NK3R
in the gonadotrope axis. Such human models are all the more
important as there is currently no genetic murine model with
Figure 4. FSH/LH ratio in 11 patients with nCHH caused by biallelic TAC3/TACR3 mutations. Panel A. Significantly higher serum FSH/ serum
LH ratios in 11 patients with nCHH caused by TAC3/TACR3 biallelic mutations than in patients with other genetic forms of CHH or in CHH patients
with no mutation found in known genes. Note the Log scale on Y axis. A whole variance analysis by Kruskal-Wallis test (p,0.0001) was performed
followed by post-hoc Newman-Keuls multiple comparison test; *indicates a significant difference between 2 groups (p,0.001). The threshold
separating FSH/LH ratio in TAC3/TACR3 mutated nCHH subjects from those of patients with other genetic forms of CHH is indicated by an horizontal
line. Panel B. Decrease in the FSH/LH ratio in one patient with TAC3 and two patients with TACR3 mutations (see Patients) during pulsatile GnRH
administration. Note the Log scale on Y axis.
doi:10.1371/journal.pone.0025614.g004
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dysfunction for hypothalamic GnRH secretion.
Methods
All the participants gave their written informed consent for
hormonal exploration and genetic analyses, in keeping with the
provisions of the French Bioethics Law and the Declaration of
Helsinki and after approval by the Bice ˆtre Hospital ethic
committee (Comite ´ de protection des personnes Ile de France,
Ho ˆpital Bice ˆtre).
Hormone assays
We measured serum levels of LH, FSH, inhibin B, testosterone
and estradiol levels with immunoradiometric assay, enzyme-linked
immunosorbent assay, or radioimmunoassay, respectively, as
previously reported [29,30]. The detection limits of the LH and
FSH assays were respectively 0.15 IU/L and 0.2 IU/L. The intra-
and interassay coefficients of variation were, respectively, 1.5 and
5.2% for LH, 2.7 and 5.5% for FSH. Endogenous luteinizing
hormone and alpha-subunit secretion, analyzed with Thomas’
algorithm, was evaluated overnight at 10-minutes intervals, as
reported elsewhere [29,30,31]. Serum free alpha-subunit (FAS)
levels were measured as previously reported [32], using an
immunoradiometric assay (IRMA) with two monoclonal antibod-
ies (Immunotech, Marseille, France). Cross-reactivity of this
immunoassay is less than 0.1% for dimeric hormones (including
CG, LH, FSH, and TSH) and 0% for the free b-subunits of these
hormones. Results are expressed as international units per liter
(IU/L) of Medical Research Council 75/569, and the detection
limit is 0.025 IU/L. Within-run and between-run coefficients of
variation are respectively 6% and 12% at a concentration of
0.3 IU/L, and 3% and 5% at a concentration of 2 IU/L. Normal
basal FAS levels are 0.9–1.9 IU/L for postmenopausal women, 0–
0.6 IU/L for premenopausal women during the early follicular
phase, and 0–0.3 IU/L for men.
For FSH/LH ratio determination, we used blood samples
drawn at diagnosis from untreated CHH patients referred to the
Endocrinology and Reproductive Diseases department of Ho ˆpital
Bice ˆtre and sera stored at 280uC. All gonadotropin assays were
performed in a single run in order to avoid interassay variations.
DNA analysis
Genomic DNA was extracted from white blood cells by using
standard procedures.
TAC3 coding exons 2, 3, 4, 5 and 6 and intron-exon junctions
and TACR3 coding exons 1, 2, 3, 4 and 5 and intron-exon
junctions were amplified by PCR and sequenced as previously
described [1,3]. Sequence variations were found on both strands
and confirmed in a separate PCR.
GNRHR, GNRH1, KISS1R, KISS1, KAL1, FGFR1 and PROK2/
PROR2 were also analyzed as previously described, with minor
modifications [29–31,33–36].
Modeling studies
The model of NK3R was generated by homology, using as
template the crystal structure of rhodopsin, a hepta-transmem-
brane protein, with the Modeller package (version 9.8) [37]. Loops
differing in length between NK3R and rhodopsin were recon-
structed using the structural proteins bank (rotamer library)
included in the O package [38]. NK3R mutants were generated
using the same package. Statistics, calculated with Procheck,
showed that .98.6% of the residues in the Ramachandran plot
are in the most favored or allowed regions and that side-chain
stereo parameters are inside the range or better than the statistics
derived from a set of crystal structures of at least 2.0 A ˚ resolution.
In addition, the PROSAII program gave a combined Z-score (Cb
and surface potentials) of 23.34, a value in the range of structured
proteins. These results suggest that the protein is of good quality
and suitable for analysis.
Directed mutagenesis
NK3R mutants were reproduced by site-directed mutagenesis
using the pcDNA3.1+ plasmid encoding human NK3R with an
hemagglutinin (HA) tag localized on the extracellular NK3R N-
terminal extremity (Missouri S&T cDNA Resource Center) with
the QuickChange Stratagen II kit (Stratagene, La Jolla, CA).
Clones were verified by sequencing.
Luciferase reporter gene assays
Tachykinin G protein-coupled receptors signal through several
second messenger pathways including phosphoinositide and MAP
kinase pathways (ERK 1/2) [39]. We thus used the luc2P/SRE/
Hygro plasmid (Promega) which can induce luciferase production
in response to MAP kinase activation as a reporter gene system
[40]. HEK 293T cells (12,000 cells/well) were seeded 72 h before
testing in high-glucose Dulbecco’s minimal essential medium
(Invitrogen, Cergy Pontoise, France) containing 2 mM glutamine,
100 IU/mL penicillin, 100 mg/mL streptomycin, and 10% heat-
inactivated fetal calf serum at 37uC in 96-well plates. Twenty-four
hours before testing, the cells were cotransfected in serum free
OptiMEM, using Lipofectamine 2000 as recommended by the
manufacturer (Invitrogen) with the plasmids coding for the wild-
type or NK3R mutants, the luc2P/SRE/Hygro plasmid (Pro-
mega) and pRSV-beta-galactosidase plasmid. On the test day,
neurokinin B was added at seven dilutions (from 10
210 to 10
26 M)
to the culture medium. After incubation for 5–6 h the cells were
harvested and assayed for b-galactosidase and luciferase activities
as previously described [41], using a luminometer (Victor, Perkin
Elmer). To standardize the transfection efficiency, the relative light
units obtained in the luciferase assay were divided by the optical
density obtained in the b-galactosidase assay. Maximum activity
was considered at 5x10
27 M NKB. Prism version 3.02 (GraphPad
Software Inc., SanDiego, CA) was used for curve fitting from at
least three independent experiments performed in triplicate.
Results are expressed as mean6SEM.
Immunocytochemistry
COS-7 cells were grown in 24-well plates containing glass
coverslips (14-mm diameter). After transfection with the expression
vector coding for HA-NK3R, cells were processed as previously
described [42]. Briefly, cells were fixed with 4% paraformaldehyde
and permeabilized for 10 min with a 0.2% solution of Triton
X100 diluted in PBS. Cells were then incubated overnight at 4uC
with an anti-HA antibody (clone 3F10, Roche Applied Science),
followed by an anti-rat fluorochrome-coupled secondary antibody
(Dylight 549, Jackson ImmunoResearch Laboratories) for 30 min.
Nuclear counterstaining was performed with 0.5 mg/mL DAPI
(49,69-diamidino-2-phenylindole). Fluorescent cells were observed
with an Olympus Provis AX70. Images were acquired with
Qcapture Pro version 5.1 (Q Imaging Inc.). For live cell staining,
cells were incubated for 1 h with the anti-HA antibody before
fixation with 2% paraformaldehyde and direct incubation with the
Dylight 549 secondary antibody. After extensive washing with
TBS-Tween (0.1%), cells were post-fixed with 2% paraformalde-
hyde and counterstained with DAPI, rinsed quickly in water, and
then mounted on slides with ProLong Gold mounting medium
(Molecular Probes). A Zeiss LSM-510 confocal scanning laser
Novel TACR3 Mutations in nCHH
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series of focal planes using a Plan Apochromat 63 oil objective.
Supporting Information
Figure S1 Schematic representation of the human NK3R
variants found in a cohort of 173 normosmic CHH. The
mutated residues are indicated by red circles (see also Table 1).
(DOC)
Figure S2 Molecular characterization of biallelic vari-
ants. DNA sequencing of the genomic region encompassing the
mutation. In-frame amino acids are indicated above each
sequence. Panel A: Molecular characterization of the TACR3
c.483_499 deletion in family 1 (see Fig. 1A). The TACR3
c.483_499 deletion (delimited by the red vertical line) leads to a
frameshift from codon 161 which is responsible for the emergence
of a premature stop codon at position 183. This frameshift
mutation was homozygous in the affected female propositus
(Subject II-6) and heterozygous in her unaffected father (Subject
I.1). A wild type homozygous unaffected sister (subject II-1) is
indicated in the upper part of the panel. This gene product is 182
amino acids long, compared to 465 aa for the full-length protein.
Only 3 transmembrane domains are encoded, rather than the 7
transmembrane domains in the wild-type receptor. Panel B:
Molecular characterization of compound heterozygous TACR3
mutations (c.824G.A and c.1003C.T) in family 2 (see Fig. 1B).
The c.824G.A substitution produces a stop codon in the fifth
transmembrane domain (p.Trp275stop = W275X) of NK3R. It
was found in the heterozygote state in the unaffected father. The
c.1003C.T substitution produces a stop codon at the junction
between the third extra cellular loop and the seventh transmem-
brane domain (p.Gln335stop = Q335X) of NK3R. This mutation
was found at the heterozygote state in the unaffected mother.
Panel C: Molecular characterization of compound heterozygous
TACR3 mutations (c.799T.A and c.824G.A) in family 3
(Fig. 1C). The c.824G.A substitution is the same as in patient
II-1 family 2, Fig. 1C. It was found in the heterozygous state in the
unaffected father. The c.799T.A substitution produces a missense
mutation (p.Tyr267Asn= Y267N) located in the fifth transmem-
brane domain of NK3R. This mutation was found in the
heterozygous state in the unaffected mother.
(DOC)
Figure S3 Molecular characterization, functional conse-
quences and modeling of Lys286Arg and Met306Ile NK3R
variants. In propositus II.2 from family 4 (panel A and panel B), we
found two variants (c.857A.G and c.918G.A). The same
variants were found in the unaffected father’s (panel A) showing that it
was not a real biallelic form. Lys286 is not conserved in the three
human tachykinin receptors but is highly conserved in all NK3R
orthologs (panel C). Using the three-dimensional model we found that
Lys286 (K286) is located in the third intracellular loop (panel D)(see
also Fig. S1). We tested the activity of the mutant receptor on the SRE
luc reporter gene (panel E (upper)) and showed that there was no
meaningful difference between the p.Lys286Arg mutant (green
squares) and the wild-type NK3R (black circles). The c.918G.A
produces a missense mutation (p.Met306Ile) located in the sixth
transmembrane segment of NK3R (Fig. S1). It is poorly conserved in
the three human tachykinin receptors and NK3R orthologs (panel C).
Using the three-dimensional model, we found that Met306 (M306) is
located at the middle of the sixth transmembrane segment and fully
surface exposed (panel D). We tested the activity of the p.Met306Ile
variant on the SRE-Luc reporter gene system (panel E (middle)) and
showed that there was no difference between the p.Met306Ile mutant
(green triangles) and the wild-type NK3R (black circles). To verify that
the p.Lys286Arg variant did not interfere with the function of the
p.Met306Ile mutant we performed a double p.Lys286Arg+p.Me-
t306Ile mutant. The activity of the double mutant on the SRE-Luc
reporter gene system (orange triangles) was similar to that in the wild-
type NK3R (black circles) (panel E (lower)).
(DOC)
Figure S4 Molecular characterization, functional con-
sequences and modeling of Arg230His NK3R variant. In
propositus II.1 from family 5 (Panels A and B) we found one
variant (c.689G.A) at the heterozygous state. This variant,
located in the second extracellular loop of NK3R, produces a
missense mutation (p.Arg230His)(see also Fig. S1). It is partly
conserved in the three human tachykinin receptors and almost
completely conserved in NK3R orthologs (Panel C). Using the
three-dimensional model, we found that Arg230 (R230) is located
in the second extracellular loop and solvent-exposed (Panel D). We
tested the activity of the mutant receptor on the SRE-Luc system
(Panel E) and showed that the Arg230His mutation has no
consequence on the receptor activity.
(DOC)
Information S1 Mutations in patients with other genetic
causes of CHH or Kallmann syndrome included for the
analysis of serum FSH/LH ratio (Fig. 4A).
(DOC)
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